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ditorialcute  radiation  syndrome  and  Fukushima:  A  watershed
oment?s we  sit down  to write this editorial in late December, it
s clear that 2011 has been a very active year for scientists
nterested in ﬁnding better ways to treat radiation-induced
njuries. The nuclear disaster that occurred in March 2011 in
ukushima, Japan was the most serious accident since the
hernobyl accident in 1986. Fukushima draws attention to the
rgent need to implement measures to prevent such accidents
rom occurring, but also to develop comprehensive emergency
lans to respond to accidental – or intentional – radiation
xposure.1
We  believe that, in the long run, the Fukushima disas-
er may come to be seen as a watershed moment, as it has
ncreased awareness of the need to better understand how to
revent and treat radiation-induced injuries, including both
arly effects—acute radiation syndrome (ARS), which primar-
ly affects the blood, skin, and gastrointestinal systems—and
ate effects, which include genetic damage, cancers, and
ataracts. Fortunately, in terms of scientiﬁc output, 2011 was
 banner year and numerous articles were published on this
opic. In this editorial, we highlight some of the most relevant
f these publications.
Remarkably, in 2011, three different medical journals, all
orking independently of each other, published special issues
evoted to acute radiation syndrome (ARS) and emergency
esponse measures to be undertaken in the event of a nuclear
eltdown and/or detonation.
In March, the journal Disaster Medicine and Public Health
reparedness (DMPHP) published a comprehensive assess-
ent of planning and response procedures in the event of
 nuclear detonation. The authors emphasize that planning
or allocation of scarce resources needs to be well-planned
eforehand.2 We  agree. Fortunately, as the authors point
ut, the U.S. government has prepared a comprehensive web
ite, called the Radiation Emergency Medical Management
ite (http://www.remm.nlm.gov/). The aim of the web site is
o provide just-in-time, evidence-based guidance for health
are providers about clinical diagnosis and treatment of radi-
tion injury during radiological and nuclear emergencies.
nother web site, the Radiation Injury Treatment Network
http://www.ritn.net/),  provides similar information.In April, the journal Clinical Oncology published a special
issue entitled “The Radiobiological Consequences of the Chernobyl
Accident 25 Years On”,3 in which they assess how the Chernobyl
experience has led to the identiﬁcation of high-risk groups
and the use of specialized techniques to collect information
on diagnosis, treatment and follow-up. One of the papers in
that issue focuses on how the study of affected populations
has provided important new data on the association between
low dose radiation and late effects, primarily the risk of thyroid
cancer,4,5 as the data show a dose-related increase in thyroid
cancer in children and adolescents exposed to radioiodines,
with the greatest risk to younger children. The authors also
report other interesting ﬁndings, including an increased risk
of cataracts, leukemia and other hematological diseases, and
a possible greater risk for cardiovascular disease in Chernobyl
survivors. This information is valuable not only for a better
understanding of the effects of radiation, but also to develop
measures of radiation protection. The knowledge acquired
from the Chernobyl experience is valuable data that can be
used in monitoring and treating Fukushima survivors.
In July, the present journal – Reports of Practical Oncol-
ogy & Radiotherapy – published a special issue (edited by
the authors of this editorial) which explored in depth all rel-
evant aspects of ARS, including radiobiology, biodosimetry
and dose assessment, medical management, decontamina-
tion, and prevention.6–11 The purpose of that special issue was
to present a comprehensive report of the latest understanding
of ARS and to provide guidelines for emergency treatment.
In addition to the 3 special issues discussed above, sev-
eral reports addressed the issue of new treatments for ARS.
Because randomized controlled trials of ARS are not possi-
ble in humans (due to obvious ethical issues), our current
approach is based mainly on data obtained from treating and
observing survivors of radiation incidents and accidents and
from data generated through laboratory research on animals.
The special issue carried out by DMPHP concluded that, in
the treatment of ARS, scientiﬁc evidence was strong for pro-
phylactic serotonin-receptor antagonist administration when
exposure is >2 Gy and topical steroids, antibiotics, and anti-
histamines for skin damage (burns, ulcers, blisters). Other
and r
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interventions with strong evidence include removal and graft-
ing of ulcers or necrosis with persistent pain, supportive care
for individuals with neurovascular syndrome, and electrolyte
replacement therapy and sedatives for patients with signiﬁ-
cant burns, hypovolemia, or shock.
Unfortunately, as discussed above, current treatments for
extreme radiation sickness are rather limited. However, a
number of new treatments may be on the way. Several new
therapies are being investigated, some partially or wholly
ﬁnanced by the US government through the Project BioShield
Act.12 One such study is investigating a drug called CBLB502,
under development by Cleveland BioLabs.13 This drug, which
was granted fast track approval by the US Food and Drug
Administration (FDA), binds an immune protein to activate
a cell survival pathway (the Toll pathway). Another study in
phase I is testing a drug designed to interrupt proteins (such
as p53) involved in cell apoptosis. Another group is working on
a technique to use bone marrow to create a stem-cell-based
treatment that would help repair organ damage incurred as
a result of radiation exposure. The direct infusion of blood
stem cells into the bloodstream to increase the number of
white blood cells is also being investigated. Yet another group
is working on a small molecule to reduce inﬂammation and
oxidative stress in acute radiation syndrome. Researchers
have also investigated interventions to prevent or alleviate
radiation lung injury. Inhibitors of angiotensin converting
enzyme (ACE), have been found to be among the most effective
mitigators of lung injury. One study found the ACE inhibitor
captopril to be effective in mitigating lung damage when
administered up to 1 week following radiation exposure.14
Transfusion of myeloid progenitor cells has been evaluated
in an animal model of ARS, with promising results: this tech-
nique has proven effective in protecting animals exposed to
lethal doses of radiation.15 Other areas of research include the
search for ways to detect genetic alterations caused by ionizing
radiation based on DNA damage-induced gene expression16
and energy metabolism.17 Several other interesting papers on
the subject of ARS were also published in 2011.18–20
To conclude, it seems that the Fukushima incident,
together with growing concerns about a potential terrorist
attack, have provided a strong impetus for the development
of emergency response plans and new research to identify
drugs capable of ameliorating the effects of ARS. In addi-
tion, researchers are already preparing studies of the long
and short-term effects of radiation on the population in the
area of Fukushima.21 We  believe that 2011 represents a tip-
ping point in efforts to prevent further nuclear accidents
and to develop new approaches in the treatment of radiation
sickness.
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